Tacrolimus
- Generic Name
- Tacrolimus
- Brand Names
- Advagraf, Astagraf, Envarsus, Modigraf, Prograf, Protopic, Tacforius
- Drug Type
- Small Molecule
- Chemical Formula
- C44H69NO12
- CAS Number
- 104987-11-3
- Unique Ingredient Identifier
- Y5L2157C4J
- Background
Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condi...
- Indication
Immediate-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. Extended-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric ...
- Associated Conditions
- Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Oral Lichen Planus, Psoriasis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Atopic Dermatitis, Vitiligo, Moderate Atopic dermatitis
- Associated Therapies
- -
Population Pharmacokinetics of Tacrolimus in Nephrotic Syndrome
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2019-08-05
- Target Recruit Count
- 200
- Registration Number
- NCT04045171
Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 10
- Registration Number
- NCT04041219
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT04022239
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 823
- Registration Number
- NCT04009525
- Locations
- 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT04002115
- Locations
- 🇺🇸
Penn State Cancer Institute, Hershey, Pennsylvania, United States
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- Radiation: Total-Body IrradiationDrug: ThiotepaDrug: FludarabineDrug: CyclophosphamideBiological: Peripheral Blood Stem CellDrug: TacrolimusBiological: Allogeneic CD34+-enriched and CD45RA-depleted PBSCsDrug: MethotrexateDrug: CyclosporineDrug: BusulfanDrug: SirolimusProcedure: Bone Marrow Aspiration and BiopsyProcedure: EchocardiographyProcedure: Multigated Acquisition ScanProcedure: Biospecimen Collection
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT03970096
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)
- Conditions
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 431
- Registration Number
- NCT03959241
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Dana Farber Cancer Institute/Brigham & Women's, Boston, Massachusetts, United States
🇺🇸Ohio State/Arthur G. James Cancer Hospital, Columbus, Ohio, United States
Tacrolimus Treatment for Refractory Autoimmune Cytopenia
- Conditions
- Interventions
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT03918265
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren Syndrome
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2019-05-22
- Lead Sponsor
- Pavly Moawd
- Target Recruit Count
- 60
- Registration Number
- NCT03865888
- Locations
- 🇪🇬
Pavly Moawad, Cairo, Egypt
Envarsus in Delayed Graft Function (E-DGF)
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 100
- Registration Number
- NCT03864926
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.